Navigation Links
Techne Corporation Declares Dividend
Date:10/28/2010

MINNEAPOLIS, Oct. 28 /PRNewswire-FirstCall/ -- Techne Corporation (Nasdaq: TECH) announced that its Board of Directors has decided to pay a dividend of $0.27 per share for the quarter ended September 30, 2010.  The quarterly dividend will be payable November 22, 2010 to all common shareholders of record on November 8, 2010.  Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Techne Corporation has two operating subsidiaries:  Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty manufacturer of biological products.  R&D Systems has two subsidiaries, BiosPacific, Inc. (BiosPacific), located in Emeryville, California and R&D Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacific is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits. R&D China and R&D Europe distribute biotechnology products.


'/>"/>
SOURCE Techne Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Techne Corporation Declares Dividend
2. Pharmos Corporation Reports 2010 Third Quarter Results
3. Baxa Corporation Announces 2011 Course Schedule for its STAR Center® Training Facility
4. United American Healthcare Corporation Names John M. Fife as Chairman of the Board
5. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
6. CVS Caremark Corporation to Hold Third Quarter 2010 Conference Call
7. Luminex Corporation Third Quarter Earnings Release Scheduled for November 4, 2010
8. Cardiogenesis Corporation to Report 2010 Third Quarter Results on November 3rd
9. Physicians Pharmaceutical Corporation Offers Innovative On-Site Drug Dispensaries
10. Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna
11. Tecan Group and Luminex Corporation Partner to Develop Automated Newborn Screening Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2020)... ... , ... LaVoieHealthScience (LHS), an integrated investor and public relations consulting ... President, CEO and Founder of LHS, has been named to the PharmaVOICE 100 ... 100 has honored more than 1,500 industry executives for their contributions to the life ...
(Date:7/31/2020)... ... July 31, 2020 , ... Member Care Solutions announced a deal with American ... operators the licensing of their cloud based membership management software platform. , “We are ... Our software is the perfect match for many reasons, but AFC’s need to quickly ...
(Date:7/22/2020)... ... July 22, 2020 , ... TrialScope, the global leader ... addition of Moderna to its growing customer roster. , TrialScope customers include 16 ... disclosure management, patient engagement and study recruitment. Collectively, TrialScope customers are responsible for ...
Breaking Medicine Technology:
(Date:8/5/2020)... ... August 05, 2020 , ... In its ... to unprecedented challenges. Regardless of the obstacle - shortages of tests, ventilators and ... and the cancellation or postponement of all nonessential services - providers across the ...
(Date:8/5/2020)... ... August 05, 2020 , ... ... industry, as president of the largest veterinarian-owned purchasing Cooperative in the United States. ... various roles where she gained extensive knowledge and experience in the animal health ...
(Date:8/5/2020)... ... August 04, 2020 , ... Total ... Autism Spectrum Disorder (ASD) in Wisconsin, is delighted to announce the grand opening ... opening of their newest center, Total Spectrum now proudly serves ten different locations ...
(Date:8/3/2020)... ... August 03, 2020 , ... Evolution ... Suite360:Mental Health and Prevention program district-wide, developed to help students navigate a range ... , Florida schools and districts must provide their students with preventative lessons after ...
(Date:8/3/2020)... ... August 03, 2020 , ... Actuate Therapeutics, Inc. ... with first-line advanced pancreatic cancer in a phase 2 study of 9-ING-41, as ... EudraCT#:2018-003739-32). 9-ING-41 is Actuate’s proprietary small molecule glycogen synthase kinase-3 beta (GSK-3ß) ...
Breaking Medicine News(10 mins):